Skip to main content
SP5007,626.93-0.77%DOW52,743.58-0.83%NASDAQ26,094.46-1.05%BTC$77,297.00-2.13%ETH$2,416.26-2.56%GOLD$4,376.50-2.34%OIL$90.48+5.50%
Smart Investors Daily
Sign InSign Up Free
Ligand Pharmaceuticals, Inc. logo

OTC · LGNXZ

Ligand Pharmaceuticals, Inc.

Healthcare · Medical - Pharmaceuticals

$0.00

Up+$0.00 (+22.28%)

Updated Sep 1, 2026, 7:46 PM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.62K
P/E ratio
99
Dividend yield
0.00%
52-week range
— – —
Volume
100
Avg. volume
62.65K

Price performance

LGNXZ price history

1M range · 0 trading sessions · Daily adjusted prices

LGNXZ does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LGNXZ news

The latest Smart Investors Daily articles mentioning LGNXZ.

Stock researchCompany · Overview

LGNXZ research

Overview

Company profile and research snapshot.

Company profile

LIGAND PHARMS GLUCAGON

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
13
LGNXZ recent ratings
DateFirmRatingTarget
Aug 14, 2026Leerink PartnersOutperform—
Aug 7, 2026RBC CapitalOutperform—
Aug 6, 2026HC Wainwright & Co.Buy—
Aug 3, 2026OppenheimerOutperform—
Jul 21, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 16, 2026

Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings

Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m...

Yahoo · Jul 14, 2026

XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the transaction announced on April 27, 2026, Ligand acquired all of the outstanding shares of XOMA Royalty common stock. XOMA Royalty stockholders received $39.00 in cash per share of XOMA Royalty common stock owned. XOMA Royalty stockholders and equity aw

Yahoo · Jul 14, 2026

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By